Search
Now showing items 1-4 of 4
Influence of the UGT2B17 Gene on the Relationship Between Exemestane and Bone Mineral Density in Postmenopausal Women
Background: In the Mammary Prevention.3 (MAP.3) randomized placebo-controlled trial of exemestane, postmenopausal women experienced a loss in bone mineral density (BMD). UGT2B17 facilitates excretion of androgens and ...
The associations between estrogens, the UGT2B17 gene deletion, and health-related quality of life in postmenopausal women in the MAP.3 chemoprevention trial
Background: Natural depletions of estrogens during menopause are likely associated with symptoms and declines in health-related quality of life (HRQL). For women taking exemestane in the Mammary Prevention 3 (MAP.3) trial, ...
UGT2B17, exemestane metabolism, and their association with physical health-related quality of life in Caucasian postmenopausal women participating in the Mammary Prevention.3 Trial
Background: In the Mammary Prevention.3 (MAP.3) trial of exemestane (EXE) for breast cancer prevention, postmenopausal women commonly reported physical menopause-related symptoms, such as joint and muscle pain and fatigue. ...
The Association between the UGT2B17 Gene Deletion and Menopause-Related Quality of Life in Postmenopausal Women in the CCTG MAP.3 Breast Cancer Chemoprevention Trial
Background: Mammary Prevention.3 (MAP.3) was a randomized placebo controlled trial of exemestane for breast cancer prevention. Participants commonly experienced vasomotor symptoms, such as hot flashes. Exemestane is ...